brain-image.jpgOxford BioMedica, a leading gene therapy company, announced yesterday new data from the ongoing Phase I/II trial of ProSavin, its gene therapy for the treatment of Parkinson’s disease. All patients treated at the second dose level have completed their six-month assessments and have shown further improvement in motor function — up to 53% improvement in patients’ motor function, with an average uptick of 34%..

(Read the story in AFP) 


Leave a Reply